Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All extracted claims concern pricing/insurance coverage/patent timing for generic Adderall XR, which are not addressed in the FDA-approved prescribing information provided (no label sections given). Therefore, the claims are appropriately treated as unsupported by the label rather than incorrect or contradictory.
Category Scores
Accurate Statements
Without insurance, a prescription for generic Adderall XR (amphetamine and dextroamphetamine extended-release capsules) can range from approximately $40 to over $150 for a 30-day supply, depending on strength.
Unsupported by the supplied FDA label information (pricing/cost not present). Marked as absent from the label.
A 20 mg dose of generic Adderall XR might cost around $50.
Unsupported by the supplied FDA label information (dose-specific pricing not present). Marked as absent from the label.
A 30 mg dose of generic Adderall XR could be closer to $90.
Unsupported by the supplied FDA label information (dose-specific pricing not present). Marked as absent from the label.
Most insurance plans cover generic Adderall XR.
Unsupported by the supplied FDA label information (insurance coverage patterns not present). Marked as absent from the label.
With insurance, out-of-pocket cost for generic Adderall XR is typically much lower, often between $10 and $50 for a 30-day supply.
Unsupported by the supplied FDA label information (out-of-pocket ranges not present). Marked as absent from the label.
Copay amounts for generic Adderall XR vary by plan.
Unsupported by the supplied FDA label information (copay variability not present). Marked as absent from the label.
Some insurance plans may require prior authorization for generic Adderall XR.
Unsupported by the supplied FDA label information (prior authorization requirements not present). Marked as absent from the label.
Some insurance plans may have specific pharmacy networks for generic Adderall XR.
Unsupported by the supplied FDA label information (network restrictions not present). Marked as absent from the label.
Generic versions of Adderall XR became available after the patent on the brand-name drug expired.
Unsupported by the supplied FDA label information (patent/timing not present). Marked as absent from the label.
The initial patent for Adderall XR was set to expire around 2018, paving the way for generic competition.
Unsupported by the supplied FDA label information (historical patent timeline not present). Marked as absent from the label.
Unsupported Statements
All listed claims related to pricing, insurance coverage/cost-sharing, prior authorization, pharmacy networks, and generic availability/patent expiration.
The provided content contains no FDA label sections addressing pricing/coverage/timing/patents; these topics are absent from the supplied prescribing information.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No prescribing, safety, contraindication, dosing, or monitoring claims were made. The claims are administrative/market/timing assertions (absent from the label), so no direct label-based safety conflict is indicated.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Claims are not supported by the supplied FDA-approved prescribing information because they concern pricing/insurance/patent timing, which are not included in labeling.
Suggested Improvement
Avoid presenting cost/coverage/timing statements as label-supported; if included, clearly attribute them to non-label sources and do not treat them as FDA labeling facts.